(Q41622161)

English

Recent advances in the pharmacological control of experimental allergic encephalomyelitis (EAE) and the implications for multiple sclerosis treatment

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 October 2017

1 reference

Europe PubMed Central

Recent advances in the pharmacological control of experimental allergic encephalomyelitis (EAE) and the implications for multiple sclerosis treatment (English)

1 reference

Europe PubMed Central

5 October 2017

multiple sclerosis

0 references

author name string

C Bolton

1

1 reference

Europe PubMed Central

5 October 2017

publication date

1 November 1995

1 reference

Europe PubMed Central

5 October 2017

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

5 October 2017

1

1 reference

Europe PubMed Central

5 October 2017

3

1 reference

Europe PubMed Central

5 October 2017

143-149

1 reference

Europe PubMed Central

5 October 2017

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12.

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Interleukin-10 prevents experimental allergic encephalomyelitis in rats.

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Biological effects of cyclosporin A: A new antilymphocytic agent

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Immunosuppression by cyclosporin A of experimental allergic encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

The influence of cyclosporin A on the development of actively induced and passively transferred experimental allergic encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

The neuropathology of chronic relapsing experimental allergic encephalomyelitis induced in the Lewis rat by inoculation with whole spinal cord and treatment with cyclosporin A.

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Permeability of the blood-brain barrier to the immunosuppressive cyclic peptide cyclosporin A.

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Cyclosporin-A treatment of experimental allergic encephalomyelitis: changes in immunological regulation and blood-CSF barrier function

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Mononuclear cell accumulation and plasma protein extravasation (PPE) during induction, remission and re-challenge of experimental allergic encephalomyelitis in the rat

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Randomised double blind controlled trial of cyclosporin in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

FK506 and rapamycin: novel pharmacological probes of the immune response

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Requirement for vasoactive amines for production of delayed-type hypersensitvity skin reactions

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Hypothalamic noradrenergic pathways exert an influence on neuroendocrine and clinical status in experimental autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Prazosin, an alpha 1-adrenergic receptor antagonist, suppresses experimental autoimmune encephalomyelitis in the Lewis rat.

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Effects of prazosin on the blood-brain barrier during experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Prazosin suppresses development of axonal damage in rats inoculated for experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Experimental allergic encephalomyelitis: the effect of 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Suppression of experimental allergic encephalomyelitis by mitoxantrone.

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Suppression of demyelination by mitoxantrone

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Pharmacological disposition of 1,4-dihydroxy-5-8-bis[[2 [(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride in the dog.

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Warning against use of intrathecal mitoxantrone

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Paraplegia after intrathecal mitozantrone

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

MS: a CNS and systemic autoimmune disease

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

MS: a localized immune disease of the central nervous system

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Cognitive change following MPTP exposure.

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Therapy of chronic relapsing experimental allergic encephalomyelitis and the role of the blood-brain barrier: elucidation by the action of Brequinar sodium

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

The detection of lipocortins 1, 2 and 5 in central nervous system tissues from Lewis rats with acute experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Lipocortin-1: cellular mechanisms and clinical relevance

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Nitric oxide-mediated neuronal injury in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F135245859500100302

21 January 2018

Identifiers

10.1177/135245859500100302

0 references

release_uiophm7w2vcuphnbqzksoto3aq

1 reference

https://api.fatcat.wiki/v0/release/uiophm7w2vcuphnbqzksoto3aq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

5 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41622161&oldid=1925284547"